España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Viridian Therapeutics
VRDN
NASDAQ
Watchlist
Leave a Comment
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$15.59
-0.02
-0.13%
Last update: 8:04 AM
15 minutes delayed
Get Report
Comment
Viridian Therapeutics (VRDN) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Viridian Therapeutics (NASDAQ:VRDN) Stock
Viridian Therapeutics Stock (NASDAQ: VRDN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, July 16, 2024
Expert Ratings For Viridian Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Viridia...
Benzinga Newsdesk
Tuesday, June 11, 2024
Wolfe Research Initiates Coverage On Viridian...
Benzinga Newsdesk
Needham Reiterates Buy on Viridian Therapeuti...
Benzinga Newsdesk
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
Viridian Therapeutics Gives Details About Pha...
Benzinga Newsdesk
Thursday, June 06, 2024
7 Analysts Assess Viridian Therapeutics: What You Need To Know
Benzinga Insights
Goldman Sachs Initiates Coverage On Viridian ...
Benzinga Newsdesk
Thursday, May 09, 2024
HC Wainwright & Co. Maintains Buy on Viridian...
Benzinga Newsdesk
Oppenheimer Maintains Outperform on Viridian ...
Benzinga Newsdesk
Ladenburg Thalmann Downgrades Viridian Therap...
Benzinga Newsdesk
B. Riley Securities Downgrades Viridian Thera...
Benzinga Newsdesk
Needham Reiterates Buy on Viridian Therapeuti...
Benzinga Newsdesk
Wednesday, May 08, 2024
Viridian Therapeutics Q1 2024 GAAP EPS $(0.79...
Benzinga Newsdesk
Thursday, March 21, 2024
B. Riley Securities Maintains Buy on Viridian...
Benzinga Newsdesk
Wednesday, March 20, 2024
Unveiling 4 Analyst Insights On Viridian Therapeutics
Benzinga Insights
Needham Maintains Buy on Viridian Therapeutic...
Benzinga Newsdesk
Thursday, February 29, 2024
HC Wainwright & Co. Reiterates Buy on Viridia...
Benzinga Newsdesk
Wednesday, February 28, 2024
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
Navigating 6 Analyst Ratings For Viridian Therapeutics
Benzinga Insights
Wedbush Maintains Outperform on Viridian Ther...
Benzinga Newsdesk
Needham Reiterates Buy on Viridian Therapeuti...
Benzinga Newsdesk
Tuesday, February 27, 2024
Viridian Therapeutics Q4 2023 GAAP EPS $(1.35...
Benzinga Newsdesk
Thursday, January 18, 2024
Viridian Therapeutics shares are trading lowe...
Benzinga Newsdesk
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
Henry Khederian
Viridian Therapeutics Prices $150M Public Off...
Benzinga Newsdesk
Wednesday, January 17, 2024
Viridian Therapeutics Announces Proposed Unde...
Benzinga Newsdesk
Monday, January 08, 2024
Viridian Therapeutics To Provide Key Updates ...
Benzinga Newsdesk
Tuesday, December 19, 2023
Oppenheimer Maintains Outperform on Viridian ...
Benzinga Newsdesk
Monday, December 18, 2023
HC Wainwright & Co. Reiterates Buy on Viridia...
Benzinga Newsdesk
Viridian Therapeutics shares are trading high...
Benzinga Newsdesk
ZimVie Agrees To Sell Its Spine Business, Joins United States Steel, PGT Innovations And Other Big Stocks Moving Higher On Monday
Avi Kapoor
Viridian Therapeutics Announces Clinical Data...
Benzinga Newsdesk
Thursday, December 14, 2023
RBC Capital Reiterates Outperform on Viridian...
Benzinga Newsdesk
Monday, December 04, 2023
Analyst Ratings for Viridian Therapeutics
Benzinga Insights
Wedbush Reiterates Outperform on Viridian The...
Benzinga Newsdesk
Tuesday, November 14, 2023
Where Viridian Therapeutics Stands With Analysts
Benzinga Insights
RBC Capital Reiterates Outperform on Viridian...
Benzinga Newsdesk
JMP Securities Maintains Market Outperform on...
Benzinga Newsdesk
Monday, November 13, 2023
Viridian Therapeutics Q3 2023 EPS $(1.09) Dow...
Benzinga Newsdesk
Friday, November 03, 2023
Viridian Therapeutics Announced That Multiple...
Benzinga Newsdesk
Thursday, November 02, 2023
Chief Operating Officer at Viridian Therapeutics Acquires Company Stock Options Worth 474,400 Shares
Benzinga Insights
Viridian Therapeutics President and CEO Awarded $16.35M Worth of Stock Options
Benzinga Insights
Tuesday, October 31, 2023
RBC Capital Maintains Outperform on Viridian ...
Benzinga Newsdesk
Wedbush Maintains Outperform on Viridian Ther...
Benzinga Newsdesk
Monday, October 30, 2023
Needham Maintains Buy on Viridian Therapeutic...
Benzinga Newsdesk
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
Lisa Levin
Viridian Therapeutics Appoints Stephen Mahon...
Benzinga Newsdesk
Thursday, October 26, 2023
Viridian Therapeutics Enters Autoinjector Pen...
Benzinga Newsdesk
Wednesday, October 04, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch